Table 3.
Clinical characteristics at biopsy and follow-up for patients with Yang-deficiency BC and non-Yang-deficiency BC.
| Characteristics | Yang-deficiency BC (n=97) | Non-Yang-deficiency BC (n=106) | P values |
|---|---|---|---|
| Age (years) | 41.0±10.9 | 39.2±12.1 | 0.271 |
| Male (n (%)) | 44 (45.4) | 67 (63.2) | 0.011 |
| BMI (kg/m2) | 24.2±4.0 | 24.7±3.4 | 0.386 |
| Smoking (n (%)) | 20(20.6) | 27(25.5) | 0.413 |
| Alcohol drinking (n (%)) | 18(18.6) | 24(22.6) | 0.473 |
| Less exercise (n (%)) | 26(26.8) | 26(24.5) | 0.711 |
| MAP(mmHg) | 99.1±13.8 | 97.3±12.6 | 0.352 |
| Urinary protein (g/d) | 1.78±1.80 | 1.58±1.32 | 0.398 |
| Serum albumin (g/L) | 37.4±6.0 | 39.6±5.5 | 0.009 |
| eGFR (ml/min) | 80.2±29.0 | 80.3±28.7 | 0.985 |
| Serum uric acid (μmol/L) | 374.2±97.6 | 389.7±103.7 | 0.275 |
| CKD stage (n (%)) | 0.989 | ||
| stage 1 | 43(44.3) | 45(42.5) | |
| stage 2 | 26(26.8) | 29(27.4) | |
| stage 3 | 25(25.8) | 28(26.4) | |
| stage 4 | 3(3.1) | 4(3.8) | |
| Treatment∗(n (%)) | 45(46.4) | 58(54.7) | 0.236 |
| Follow-up (months) | 64.6±17.8 | 63.4±14.5 | 0.600 |
| Endpoint event (n (%)) | 23(23.7) | 9(8.5) | 0.003 |
∗Corticosteroid and/or immunosuppressant treatments; BMI: body mass index; MAP: mean arterial pressure; eGFR: estimated glomerular filtration rate; CKD: chronic kidney disease; endpoint event: 50% decline in eGFR or end-stage renal disease.